Marker Therapeutics reports FY2022 net loss of $29.9M; cash runs into Q3 2023; suspends frank relapse enrollment

Marker Therapeutics, Inc.

Net loss $29.9M for FY2022, improved from $41.9M in prior year.
Cash and cash equivalents $11.8M at Dec 31, 2022; expected to fund operations into Q3 2023.
Suspended enrollment of frank relapse patients in ARTEMIS trial after no objective responses; re-evaluating modifications.
MT-401 showed MRD+ responses: one patient bridged to transplant, another with 70% PCR reduction; data expected H2 2023.
Wilson Wolf services agreement provided $8M upfront; Lincoln Park equity facility for up to $25M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.